Spectacular Market Launches Key To Enduring Success Of Brands In Asia - IMS Health
This article was originally published in The Pink Sheet Daily
Data show that "pharmerging" markets, will grow at 14-17%, while the U.S. will lag with 3-6% growth, Europe will grow at an even slower rate of 1-4% and Japan will move at 2-5% in the next four years, underscoring the importance of Asian markets, IMS stresses.
You may also be interested in...
"Roche May Be Right" In Not Taking To Generic Drugs - IMS Health; "Innovation Surge" From 2016 Will Help Big Pharma
MUMBAI - Global pharmaceutical companies - traditionally originators of blockbuster drugs - may not be expected to become part of a "long list of generic players" even by 2020, according to leading industry data and consulting firm IMS Health. However, experts believe MNCs will pursue specific areas where their skill sets can offer competitive advantages
SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.